India is preparing to attack the global market for Wuhan pneumonia vaccines | TechNews

Vaccines are viewed by European and American countries as a tool to defeat Wuhan’s pneumonia epidemic (new corona pneumonia, COVID-19), and all vaccines have been released one by one. However, India, the world’s largest vaccine producer and with a market share of over 60%, is a major vaccine producer. But there is news on the development and production of vaccines. Naturally, it is impossible for India, as a major vaccine country, to be absent from the commercial opportunity for vaccines. Biotech factories have been preparing to expand their production capacity and are ready to meet business opportunities from demand for no-order vaccine production.

The scale of India’s biomedical industry reaches 400 billion US dollars, and vaccines are also a major producing country, accounting for more than 60% of the world. Although the new vaccines of the current crown, be it the Pfizer or Moderna vaccines, do not have the participation of India, India will not be absent from the new commercial opportunity of the crown vaccine and then participate in the production of 8 lower-priced vaccines, including Covishield from AstraZeneca. Covishield will postpone the market until 2021 due to the discovery of insufficient protection for the elderly.

India is fully confident of playing a significant role in the new crown vaccine production opportunity, and the Australian Ambassador to India is equally confident. He believes that although many countries are producing vaccines, if sufficient quantities are to be produced for the population of all countries in the world, only India can. Do it.

The Serum Institute of India, the world’s largest vaccine manufacturer, has stockpiled 50 million doses of the AstraZeneca vaccine. The calculation is that once the UK and India allow the emergency launch of the AstraZeneca vaccine, they will breathe a sigh of relief. There will be a lot of demand. The Serum Institute of India plans to produce a total of 400 million doses of Covishield vaccine by July 2021 and is expanding its production line to achieve a total production capacity of 1 billion doses per year.

Pharmaceutical packaging manufacturer Schott Kaisha is increasing production capacity for single-dose vaccine vial packaging, while Deutsche Post DHL Group is planning how to deliver hundreds of millions of doses of vaccines to countries around the world. The Serum Institute of India confidently considers production capacity and costs. India may become an important key to ending the global epidemic. Although India’s vaccine production will also be used to meet India’s own needs, India has already infected more than 10 million people, and the Indian government is destined to promote large-scale vaccine injections, but even if the India itself can use hundreds of millions of vaccines, half of the production capacity can still be supplied abroad.

Bharat Biotech is also developing vaccines and is seeking emergency government permits. Currently, Bharat Biotech has discussed the supply of vaccines with more than ten countries, including South America, Asia and Eastern Europe. Russia is currently pushing the self-developed Sputnik V (Sputnik V) vaccine, but if it wants to expand its application, it also needs Indian production capacity. Currently, Russia has signed a contract with an Indian company to manufacture the Sputnik V vaccine. More than 100 million doses will be produced.

India’s vaccine supply chain is on the move

By virtue of the seemingly limitless business opportunities, many companies in the Indian vaccine supply chain have started to expand their investment even if they do not have orders on hand, including Schott Kaisha. Schott Kaisha is currently negotiating bottling orders with 10 vaccine manufacturers in India and abroad. The current annual production capacity is 300 million doses and production capacity is expected to expand to 1.5 billion doses per year in 2021. The SGD Pharma India and Piramal Glass pairs are also expanding their production capacity or transferring other lines of products to the bottling of vaccines. SGD Pharma India currently has a total capacity of 350 million doses and currently plans to increase its capacity by 100 million doses. Piramal Glass said that if there is an unexpected temporary order, through the deployment of the production line, the vaccine bottling capacity can be doubled in a month.

Related downstream manufacturers, including syringes and cold chain transport, are also cooperating with the expansion of production capacity. The Hindustan Syringes Syringe Factory will expand production by 42% in the first half of 2021, increasing its production capacity to 1 billion units; Cold chain transporter Snowman Logistics (Snowman Logistics will also expand vaccine shipments to 200 million doses in March 2021. The Serum Institute of India will reduce production of other vaccines to free up storage and transportation capacity for use when shipped the COVID-19 vaccine.

The entire chain of the vaccine industry up and down, from vaccines to logistics, is fully prepared for the anticipated large-scale global vaccine delivery. The only problem is that if the vaccine is not as effective as expected or the epidemic begins to subside naturally, there is no need for a worldwide application. When so many vaccines are administered, what should be done with these supercapacities? Even if the production capacity is transferred back to the vaccines originally produced during the production period, there may not be such a great demand. The production line may only be able to breed mosquitoes.

(Source of the first image: shutterstock)

Other readings: